Acetamide

Acetamide

SCHEMBL3579500

CC(N)=O.NNC1(N2CCCCC2)COC(=O)N1c1ccccc1

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
TP53 P04637 1/20 0.34
TSHR P16473 2/20 0.34
IDH1 O75874 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
CYP3A4 P08684 3/20 0.32
CYP2C19 P33261 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
HIF1A Q16665 1/20 0.32
GRIN1 Q05586 2/20 0.32
GRIN2A Q12879 2/20 0.32
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
MAPK1 P28482 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3578040 0.74 IDH1 (0.33) ALDH1A1MAPTKDM4EIDH1SMN1; SMN2
SCHEMBL2725134 0.73 GRIN1 (0.35) ALDH1A1MAPTTP53TSHRIDH1
SCHEMBL3570167 0.73 IDH1 (0.38) ALDH1A1IDH1CYP2C19CYP1A2CYP2C9
Methane SCHEMBL3623097 0.72 GRIN1 (0.34) ALDH1A1MAPTTP53TSHRIDH1
Propene SCHEMBL3656717 0.70 GRIN1 (0.33) ALDH1A1IDH1SMN1; SMN2CYP2C19CYP1A2
SCHEMBL7812799 0.69 ALDH1A1 (0.35) ALDH1A1IDH1CYP2C19CYP1A2CYP2C9
SCHEMBL4359880 0.68 MAPT (0.36) ALDH1A1MAPTKDM4ETSHRIDH1
Thioacetamide SCHEMBL3574228 0.67 GRIN1 (0.33) ALDH1A1MAPTKDM4ETP53TSHR
SCHEMBL3570224 0.64 ALDH1A1 (0.33) ALDH1A1MAPTKDM4ETSHRIDH1
SCHEMBL20340441 0.64 IDH1 (0.46) ALDH1A1MAPTKDM4ETSHRIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729269-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2014-05-20 US disclosed
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED 2010-06-10 US disclosed
US-7687627-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2010-03-30 US disclosed
EP-1664038-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY Wockhardt Limited (IN) 2006-06-07 EP disclosed
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED 2005-06-30 US disclosed
WO-2005054234-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED (IN) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY GMPS, MPO, ARG1 ALDH1A1 1960/4885MAPT 4464/4885KDM4E 522/4885
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy GMPS, MPO, ARG1 ALDH1A1 1960/4885MAPT 4464/4885KDM4E 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.